27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Verge Genomics has announced a three-year collaboration with Eli Lilly And Co (NYSE:LLY) to research and develop novel therapies to treat amyotrophic lateral sclerosis (ALS), a motor neuron disease.
- Under the terms of the three-year agreement, Verge will receive up to $25 million in upfront equity investment and potential near-term payments, with an additional milestone value of $694 million and potential downstream royalties.
- Verge will apply its all-in-human platform to discover and validate new targets for ALS. The all-in-human platform is based on a proprietary collection of patient brain transcriptomes across various neurodegenerative diseases.
- Verge will apply its human-based discovery capabilities to validate targets.
- Lilly will select up to four targets identified by Verge with plans to advance through clinical development and commercialization.
- Price Action: LLY shares are down 1.75% at $231.70 in the premarket session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!